Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 5/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 5/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 5/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | ESR1 | P03372 | 6/20 | 0.34 |
| ▸ | ESR2 | Q92731 | 6/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | ESRRB | O95718 | 1/20 | 0.34 |
| ▸ | ESRRA | P11474 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30317642 | 0.80 | FLT1 (0.39) | POLBALDH1A1 | |
| SCHEMBL398775 | 0.80 | FLT1 (0.39) | POLBALDH1A1 | |
| SCHEMBL30493123 | 0.77 | TLR8 (0.35) | HSD17B10CYP1A2ESR1ESR2LMNA | |
| SCHEMBL29496596 | 0.77 | C1S (0.38) | CYP11B1CYP11B2CYP1A2MEN1KMT2A | |
| SCHEMBL396312 | 0.77 | NOS1 (0.36) | CYP11B1CYP11B2CYP1A2MEN1POLB | |
| SCHEMBL31146629 | 0.73 | JUN (0.39) | HSD17B10KDM4E | |
| SCHEMBL3373707 | 0.73 | C1S (0.43) | CYP17A1CYP3A4CYP11B1CYP11B2HSD17B10 | |
| SCHEMBL11113178 | 0.73 | — | — | |
| SCHEMBL31729204 | 0.72 | HSD17B10 (0.38) | CYP17A1CYP3A4CYP11B1CYP11B2HSD17B10 | |
| SCHEMBL11127575 | 0.72 | MTNR1A (0.32) | CYP3A4CYP1A2ESR1ESR2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7989452-B2 | Sterile injectible solution of drug in solvent or diluent | BIONICHE TEORANTA (IE) | 2011-08-02 | — | — | US | disclosed |
| US-7220858-B2 | Synthesis of hydrazine and chlorinated derivatives of bicyclic pyridazines | BARBEAU PHARMA, INC. (US) | 2007-05-22 | — | — | US | disclosed |
| US-20050137198-A1 | Stable hydrazalazine pharmaceutical compositions | BIONICHE TEORANTA | 2005-06-23 | — | — | US | disclosed |
| US-20050137397-A1 | Synthesis of hydrazine derivatives of pyridazine | BIONICHE TEORANTA | 2005-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137198-A1 | Stable hydrazalazine pharmaceutical compositions | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, SPOP, H1-5 | CYP17A1 1007/4885CYP3A4 159/4885CYP11B1 356/4885 |
| US-20050137397-A1 | Synthesis of hydrazine derivatives of pyridazine | DHPS, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HPD | CYP17A1 3120/4885CYP3A4 193/4885CYP11B1 644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.